Study of Zr-89-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer

Autor: Otto S. Hoekstra, Egbert F. Smit, Guus A.M.S. van Dongen, Berlinda van de Veen, Adrianus J. de Langen, Idris Bahce, Marc C. Huisman, Danielle J. Vugts, Daniela E Oprea Lager, Anna-Larissa N. Niemeijer, Ronald Boellaard, Erik Thunnissen
Přispěvatelé: Pulmonary medicine, Radiology and nuclear medicine, AII - Cancer immunology, AII - Inflammatory diseases, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, Amsterdam Neuroscience - Brain Imaging, CCA - Cancer Treatment and quality of life, Pathology, Intensive care medicine
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63(3), 362-367
Niemeijer, A-L N, Oprea-Lager, D E, Huisman, M C, Hoekstra, O S, Boellaard, R, de Wit-van der Veen, B J, Bahce, I, Vugts, D J, van Dongen, G A M S, Thunnissen, E, Smit, E F & de Langen, A J 2022, ' Study of 89 Zr-Pembrolizumab PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 63, no. 3, pp. 362-367 . https://doi.org/10.2967/jnumed.121.261926, https://doi.org/10.2967/jnumed.121.261926
ISSN: 0161-5505
1535-5667
Popis: The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for selecting non-small cell lung cancer (NSCLC) patients for single-agent treatment with pembrolizumab, a programmed cell death 1 (PD-1) monoclonal antibody. However, not all patients respond to therapy. Better understanding of in vivo drug behavior may help in the selection of patients who will benefit the most. Methods: NSCLC patients eligible for pembrolizumab mono-therapy as first- or later-line therapy were enrolled. Patients received 2 injections of 89Zr-pembrolizumab, 1 without a preceding dose of pembrolizumab and 1 with a preceding dose of 200 mg of pembrolizumab, directly before tracer injection. Up to 4 PET/CT scans were obtained after tracer injection. After imaging acquisition, patients were treated with 200 mg of pembrolizumab every 3 wk. Tumor uptake and tracer biodistribution were visually assessed and quantified as the SUV. Tumor tracer uptake was correlated with PD-1 and PD-L1 expression and response to pembrolizumab treatment. Results: Twelve NSCLC patients were included. One patient experienced grade 3 myalgia after tracer injection. 89Zr-pembrolizumab was observed in the blood pool, liver, and spleen. Tracer uptake was visualized in 47.2% of 72 tumor lesions measuring BXP20 mm in the long-axis diameter, and substantial uptake heterogeneity was observed within and between patients. Uptake was higher in patients with a response to pembrolizumab treatment (n 5 3) than in patients without a response (n 5 9), although this finding was not statistically significant (median SUVpeak, 11.4 vs. 5.7; P 5 0.066). No significant correlations were found with PD-L1 or PD-1 immunohistochemistry. Conclusion: 89Zr-pembrolizumab injection was safe, with only 1 grade 3 adverse event-possibly immune-related-in 12 patients. 89Zr-pembrolizumab tumor uptake was higher in patients with a response to pembrolizumab treatment but did not correlate with PD-L1 or PD-1 immunohistochemistry.
Databáze: OpenAIRE
Externí odkaz: